Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol 2009; 10:786–93. , , , , .
Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev 1998; 164:231–9. .
Efficient and selective presentation of antigen–antibody complexes by rheumatoid factor B cells. J Exp Med 1991; 173:487–9. , .
Cytokine-producing B lymphocytes – key regulators of immunity. Curr Opin Immunol 2008; 20:332–8. .
Splenic T zone development is B cell dependent. J Exp Med 2001; 194:1649–60. , , .
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2:764–6. .
et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001; 31:2726–32. , ,
et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167:1072–80. , ,
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006; 65 (Suppl. 3):iii34–6. .
et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20:785–98. , ,
et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20:441–53. , ,
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13:543–51. , , , , .
et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201:195–200. , ,
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148:11–23. , , , .
et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36:365–72. , ,
et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109:59–68. , ,
et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005; 1050:34–9. , ,
et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115:3083–92. , ,
et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008; 180:1938–47. , ,
B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19:327–36. , , .
BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006; 18:263–75. , .
et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995–9. , ,
et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008; 111:1004–12. , ,
An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev 2006; 5:235–46. , , , .
et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201:1375–83. , ,
et al. Selective activation of TACI by syndecan-2. Blood 2006; 107:3235–42. , ,
The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17:282–9. .
BAFF, APRIL and human B cell disorders. Semin Immunol 2006; 18:305–17. , , , .
et al. Multiple signaling pathways promote B lymphocyte stimulator (BLyS)-dependent B cell growth and survival. Blood 2007; 111:750–60. , ,
et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006; 25:403–15. , ,
BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21:231–64. , , , .
Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18:279–88. , , , , , .
et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293:2111–14. , ,
et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008; 9:1379–87. , ,
Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev 2004; 197:89–101. .
et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112:286–97. , ,
et al. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 2009; 182:2113–23. , ,
et al. Factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004; 173:2331–41. , ,
Regulation of the T-independent humoral response by TACI. Immunity 2001; 14:573–82. , , .
Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003; 198:1157–69. , , , .
Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006; 18:290–6. .
TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007; 109:2961–7. , , , , , .
et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008; 118:2887–95. , ,
et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004; 101:3903–8. , ,
TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008; 19:263–76. , .
Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199:1631–40. , , , , , .
et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007; 178:7531–9. , ,
Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 2007; 37:1785–95. , , , , , .
et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204:1959–71. , ,
et al. BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur J Immunol 2007; 37:990–1000. , ,
et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173:807–17. , ,
Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008; 105:14993–8. , , , .
B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol 2008; 180:7394–403. , , .
Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002; 32:163–73. , , , .
IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174:2499–506. , , , , .
Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002; 360:646. , , , , .
et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008; 131:1455–63. , ,
et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol 2004; 251:1498–501. , ,
Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus 2009; 18:78–80. , , , , , .
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007; 66:700–3. , , , , , .
BAFF blockade for systemic lupus erythematosus – will the promise be fulfilled? Immunol Rev 2008; 223:156–74. , .
et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10:R109. , ,
et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res 2009 (in press)., ,
et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008; 58:61–72. , ,
et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008; 35:1256–64. , ,
et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 2005; 17:1081–92. , ,
et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174:864–70. , ,
et al. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 2007; 56:3202–14. , ,
B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008; 4:557–67. .
Rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358:2646; author reply 7. , .
et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 2006; 18:1473–85. , ,
et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007; 56:1134–44. , ,
et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006; 8:R51. , ,
Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004; 202:496–502. , , , , , .
et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103:2770–5. , ,
Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren's syndrome. Lab Invest 2003; 83:357–65. , , , .
et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003; 62:168–71. , ,
et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97:3370–5. , ,
et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166:6–10. , ,
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313–19. , , , .
et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48:3475–86. , ,
et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007; 178:2872–82. , ,
et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10:778–85. , ,
et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116:724–34. , ,
et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173:3524–34. , ,
et al. Prevention of murine anti-phospholipid syndrome by BAFF blockade. Arthritis Rheum 2008; 58:2824–34. , ,
et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199:91–8. , ,
et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180:3655–9. , ,
et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 2004; 50:1884–96. , ,
et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003; 170:4818–25. , ,
A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci USA 2003; 100:12905–10. , , , , .
A role for BLyS in tissue inflammation? Arthritis Rheum 2003; 48:882–5. .
Updates from B Cell trials: efficacy. J Rheumatol 2006; 77:12–17. .
et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142–50. , ,